The role of Ca 19-9 in progression, recurrence and survival of borderline resectable pancreatic cancer

被引：0
|
作者：
Almeida, C. [1 ]
Goncalves, M. [1 ]
Freitas, M. [1 ]
Teixeira, C. [1 ]
Couto, M. [1 ]
Lemos, T. [1 ]
Meireles, S. [1 ]
Rego, I. [1 ]
Sarmento, C. [1 ]
Coelho, A. [1 ]
Costa, A. [1 ]
Barbosa, M. [1 ]
机构：
[1] Ctr Hosp Sao Joao, Porto, Portugal
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.426
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-370
引用
收藏
页码：S143 / S144
页数：2
相关论文
共 50 条
  • [1] The Association Between Elevated CA 19-9 and Recurrence, Site of Recurrence, and Overall Survival in Upfront Resectable Pancreatic Cancer
    Powers, B.
    Kim, J. K.
    Deperalta, D. K.
    Ogami, T.
    Pimiento, J.
    Hodul, P. J.
    Malafa, M. P.
    Fleming, J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S145 - S146
  • [2] The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer
    Kang, Chang Moo
    Kim, Jun Young
    Choi, Gi Hong
    Kim, Kyung Sik
    Choi, Jin Sub
    Lee, Woo Jung
    Kim, Byong Ro
    JOURNAL OF SURGICAL RESEARCH, 2007, 140 (01) : 31 - 35
  • [3] Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival
    Rose, J. Bart
    Edwards, Alicia M.
    Rocha, Flavio G.
    Clark, Carolyn
    Alseidi, Adnan A.
    Biehl, Thomas R.
    Lin, Bruce S.
    Picozzi, Vincent J.
    Helton, W. Scott
    ONCOLOGIST, 2020, 25 (10): : 859 - 866
  • [4] CA19-9 as a Predictor of Resectability in Patients with Borderline Resectable Pancreatic Cancer
    He, Zhaopeng
    Lu, Huimin
    Du, Xiaojiong
    Hu, Weiming
    Tian, Bole
    Zhang, Zhaoda
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 900 - 903
  • [5] No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer
    Liu, Hao
    D'Alesio, Mark
    AlMasri, Samer
    Hammad, Abdulrahman
    Desilva, Annissa
    Lebowitz, Steven
    Rieser, Caroline
    Ashwat, Eishan
    Hampton, Erica
    Khachfe, Hussein
    Laffey, Mckenna
    Singhi, Aatur
    Bahary, Nathan
    Lee, Kenneth
    Zureikat, Amer
    Paniccia, Alessandro
    HPB, 2023, 25 (05) : 521 - 532
  • [6] Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma
    Rudnicki, J.
    Agrawal, A. K.
    Grzebieniak, Z.
    Zukrowski, P.
    Zysko, D.
    Jelen, M.
    Kielan, W.
    Sebastian, M.
    Slonina, J.
    Marek, G.
    Duda-Barcik, L.
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2010, 48 (02) : 249 - 261
  • [7] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Fleming, Jason B.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Vauthey, Jean-Nicolas
    Abdalla, Eddie K.
    Sun, Charlotte C.
    Wang, Huamin
    Crane, Christopher H.
    Lee, Jeffrey H.
    Tamm, Eric P.
    Abbruzzese, James L.
    Evans, Douglas B.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) : 1794 - 1801
  • [8] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Matthew H. G. Katz
    Gauri R. Varadhachary
    Jason B. Fleming
    Robert A. Wolff
    Jeffrey E. Lee
    Peter W. T. Pisters
    Jean-Nicolas Vauthey
    Eddie K. Abdalla
    Charlotte C. Sun
    Huamin Wang
    Christopher H. Crane
    Jeffrey H. Lee
    Eric P. Tamm
    James L. Abbruzzese
    Douglas B. Evans
    Annals of Surgical Oncology, 2010, 17 : 1794 - 1801
  • [9] Hs-CRP, Albumin, and CA 19-9 After Neoadjuvant Therapy Predict Postoperative Survival in Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Nurmi, A.
    Mustonen, H.
    Stenman, U. H.
    Haglund, C.
    Seppanen, H.
    PANCREAS, 2018, 47 (10) : 1414 - 1414
  • [10] Can CA 19-9 predict inferior surgical and pathological outcomes for resectable pancreatic cancer?
    Jabbal, Iktej Singh
    Nagarajan, Arun
    Roy, Mayank
    Rivera, Carlos
    Yaghi, Marita
    Liang, Hong
    Nguyen, Timmy Q.
    George, Tiffany L.
    Nahleh, Zeina A.
    Simpfendorfer, Conrad H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16288 - E16288
12345